Dual GLP-1/GIP receptor agonist tirzepatide was recently proposed to significantly reduce body weight by up to 10.5% at 6 months (384) or 18.5% at 1 year (385) after therapy initiation and improve HbA1c and time in range in humans with overweight/obesity and T1D while being well tolerated. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.